Table 1.
Baseline clinical and demographic characteristics of the patients.
| NYU | Vanderbilt | |||
|---|---|---|---|---|
| n | 121 | 30 | ||
| Age | Mean (SD) | 59.82 (15.46) | 60.12 (12.8) | |
| Gender | Male | n (%) | 80 (66.1) | 21 (70.0) |
| Female | n (%) | 41 (33.9) | 9 (30.0) | |
| ECOG score | 0 | n (%) | 87 (71.9) | 11 (36.6) |
| 1 | n (%) | 23 (19.0) | 17 (56.7) | |
| 2 | n (%) | 5 (4.1) | 1 (3.3) | |
| 3 | n (%) | 0 (0) | 1 (3.3) | |
| Unknown | n (%) | 6 (5.0) | 0 (0.0) | |
| Histologic type | Superficial Spreading | n (%) | 17 (14.0) | 11 (36.6) |
| Nodular | n (%) | 39 (32.2) | 8 (26.7) | |
| Other | n (%) | 15 (12.4) | 3 (10.0) | |
| Unclassified | n (%) | 50 (41.3) | 8 (26.7) | |
| Stage at treatment initiation | Stage IIIB | n (%) | 5 (4.1) | 0 (0) |
| Stage IIIC | n (%) | 14 (11.6) | 0 (0) | |
| Stage IV | n (%) | 102 (84.3) | 30 (100.0) | |
| Immunotherapy treatment category | Anti-CTLA-4 | n (%) | 77 (63.6) | 4 (13.3) |
| Anti-PD-1 | n (%) | 26 (21.5) | 16 (53.3) | |
| Combination | n (%) | 18 (14.9) | 10 (33.3) | |
| Best response | CR | n (%) | 24 (19.8) | 5 (16.7) |
| PR | n (%) | 19 (15.7) | 10 (33.3) | |
| POD | n (%) | 78 (64.5) | 15 (50.0) | |
| Time to best response (months) | Median (IQR) | 3.4 (4.7) | 2.3 (1.2) | |
| Alive status | Alive | n (%) | 56 (46.3) | 16 (53.3) |
| Dead | n (%) | 65 (53.7) | 14 (46.7) | |
| Time to last follow-up (months) | Median (IQR) | 14.0 (34.6) | 28.5 (32.5) | |
*
IQR, interquartile range